1967 related articles for article (PubMed ID: 18843661)
21. WITHDRAWN: Ovarian ablation for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000485. PubMed ID: 18843610
[TBL] [Abstract][Full Text] [Related]
22. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
Jonat W
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
25. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Hind D; Wyld L; Beverley CB; Reed MW
Cochrane Database Syst Rev; 2006 Jan; (1):CD004272. PubMed ID: 16437480
[TBL] [Abstract][Full Text] [Related]
26. [The role of hormonal ovarian ablation in adjuvant treatment of premenopausal breast cancer].
Murtezani Z; Nešković-Konstantinović Z; Stanisavljević N; Kovčin V
Srp Arh Celok Lek; 2011; 139(5-6):339-46. PubMed ID: 21858973
[TBL] [Abstract][Full Text] [Related]
27. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
28. Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
[TBL] [Abstract][Full Text] [Related]
29. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet Oncol; 2022 Mar; 23(3):382-392. PubMed ID: 35123662
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
32. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
[TBL] [Abstract][Full Text] [Related]
33. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
34. LHRH-agonist versus chemotherapy in premenopausal breast cancer?
Klijn JG
Eur J Cancer; 2002 Nov; 38 Suppl 6():S45-6. PubMed ID: 12409071
[No Abstract] [Full Text] [Related]
35. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
36. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI
Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
[TBL] [Abstract][Full Text] [Related]
37. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient.
Jonat W; Pritchard KI; Sainsbury R; Klijn JG
J Cancer Res Clin Oncol; 2006 May; 132(5):275-86. PubMed ID: 16435142
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant endocrine therapy for premenopausal women: Type and duration.
Francis PA
Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
[TBL] [Abstract][Full Text] [Related]
39. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
Love RR; Duc NB; Allred DC; Binh NC; Dinh NV; Kha NN; Thuan TV; Mohsin SK; Roanh le D; Khang HX; Tran TL; Quy TT; Thuy NV; Thé PN; Cau TT; Tung ND; Huong DT; Quang le M; Hien NN; Thuong L; Shen TZ; Xin Y; Zhang Q; Havighurst TC; Yang YF; Hillner BE; DeMets DL
J Clin Oncol; 2002 May; 20(10):2559-66. PubMed ID: 12011136
[TBL] [Abstract][Full Text] [Related]
40. Role of adjuvant endocrine therapy in early-stage breast cancer.
Muss HB
Semin Oncol; 2001 Aug; 28(4):313-21. PubMed ID: 11498825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
